Technical Analysis for STX - Shield Therapeutics Plc

Grade Last Price % Change Price Change
F 38.65 7.36% 2.65
STX closed up 1.41 percent on Wednesday, March 3, 2021, on 1.79 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical STX trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 7.36%
NR7 Range Contraction 7.36%
Doji - Bullish? Reversal 7.36%
Lower Bollinger Band Walk Weakness 7.36%
New 52 Week Low Weakness 7.36%
Wide Bands Range Expansion 7.36%
Below Lower BB Weakness 7.36%
Oversold Stochastic Weakness 7.36%
New 52 Week Closing Low Bearish 8.87%
Lower Bollinger Band Walk Weakness 8.87%
Older End-of-Day Signals for STX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 10% 11 minutes ago
Down 2% 11 minutes ago
Down 1% 11 minutes ago
Rose Above Previous Day's High 11 minutes ago
2x Volume Pace 11 minutes ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Shield Therapeutics Plc Description

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Health Iron Pharmaceutical Medicine Clinic Pipe Pharmaceuticals Hospital Disease Clinical Trial Blood Pharmaceutical Industry Rtt Phosphate Clinical Research Kidney Disease Chronic Kidney Disease Design Of Experiments Anemia Inflammatory Bowel Disease

Is STX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 153.0
52 Week Low 34.0
Average Volume 834,742
200-Day Moving Average 96.10
50-Day Moving Average 54.28
20-Day Moving Average 48.73
10-Day Moving Average 46.29
Average True Range 4.59
ADX 33.5
+DI 12.42
-DI 37.44
Chandelier Exit (Long, 3 ATRs ) 43.24
Chandelier Exit (Short, 3 ATRs ) 47.76
Upper Bollinger Band 60.43
Lower Bollinger Band 37.03
Percent B (%b) -0.04
BandWidth 48.02
MACD Line -4.92
MACD Signal Line -3.71
MACD Histogram -1.2125
Fundamentals Value
Market Cap 42.24 Million
Num Shares 117 Million
EPS 3.60
Price-to-Earnings (P/E) Ratio 10.00
Price-to-Sales 19.50
Price-to-Book 4.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.50
Resistance 3 (R3) 40.33 38.67 39.75
Resistance 2 (R2) 38.67 37.52 38.75 39.50
Resistance 1 (R1) 37.33 36.81 38.00 37.50 39.25
Pivot Point 35.67 35.67 36.00 35.75 35.67
Support 1 (S1) 34.33 34.52 35.00 34.50 32.75
Support 2 (S2) 32.67 33.81 32.75 32.50
Support 3 (S3) 31.33 32.67 32.25
Support 4 (S4) 31.50